KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to -$765.0 million.

  • Pfizer's Deferred Taxes rose 5515.83% to -$765.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 billion, marking a year-over-year increase of 2886.38%. This contributed to the annual value of -$2.1 billion for FY2024, which is 3893.09% up from last year.
  • As of Q3 2025, Pfizer's Deferred Taxes stood at -$765.0 million, which was up 5515.83% from -$272.0 million recorded in Q2 2025.
  • In the past 5 years, Pfizer's Deferred Taxes ranged from a high of $203.0 million in Q2 2021 and a low of -$3.6 billion during Q4 2021
  • Its 5-year average for Deferred Taxes is -$1.2 billion, with a median of -$774.0 million in 2024.
  • In the last 5 years, Pfizer's Deferred Taxes soared by 14756.1% in 2021 and then crashed by 162727.27% in 2022.
  • Pfizer's Deferred Taxes (Quarter) stood at -$3.6 billion in 2021, then rose by 5.84% to -$3.4 billion in 2022, then skyrocketed by 45.34% to -$1.9 billion in 2023, then increased by 8.18% to -$1.7 billion in 2024, then skyrocketed by 55.16% to -$765.0 million in 2025.
  • Its Deferred Taxes stands at -$765.0 million for Q3 2025, versus -$272.0 million for Q2 2025 and -$663.0 million for Q1 2025.